Skip to main content
Menu
US

HTRF AAV8 Detection Kit, 500 Assay Points

The AAV8 Capsid kit is designed for the quantitative measurement of Adeno-associated virus serotype 8 (AAV8) particles in both cell lysates and cell supernatants.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Click to copy promo code to clipboard.
SAVE 15% NOW on online orders. Use promo code below.
YEAREND15
Offer valid until 12/15. Terms and conditions apply.
Feature Specification
Application Bioprocessing
Sample Volume 5 µL

The AAV8 Capsid kit is designed for the quantitative measurement of Adeno-associated virus serotype 8 (AAV8) particles in both cell lysates and cell supernatants.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Click to copy promo code to clipboard.
SAVE 15% NOW on online orders. Use promo code below.
YEAREND15
Offer valid until 12/15. Terms and conditions apply.
Product Variants
Unit Size: 500 Assay Points
Part #:
64AAV8PEG
List Price
USD 2,207.00
Unit Size: 10,000 Assay Points
Part #:
64AAV8PEH
List Price
USD 22,820.00

Overview

Adeno-associated virus (AA) vectors are the leading platform for gene delivery for the treatment of a variety of human diseases. AAV Serotype 8 (AAV8) when used as vector in gene therapy, has a liver cell transduction efficiency greater than those of other serotypes which has resulted in efforts to develop this virus as a gene therapy vector for hemophilia. AAV8 also exhibits a natural tropism for other tissues such as brain, muscle and retina. The AAV8 kit is designed to detect and quantify AAV8 particles in an easy-to-use, no-wash format. The simple and robust procedure benefits from increased throughput compared to ELISA.

Specifications

Application
Bioprocessing
Brand
HTRF
Detection Modality
HTRF
Lysis Buffer Compatibility
Lysis Buffer 1
Lysis Buffer 2
Lysis Buffer 3
Lysis Buffer 4
Product Group
Kit
Sample Volume
5 µL
Shipping Conditions
Shipped in Dry Ice
Target Class
Viral Particles
Technology
TR-FRET
Unit Size
500 Assay Points

Video gallery

How it works

AAV8 capsid assay principle

The Adeno-Associated Virus serotype 8 (AAV8) assay measures AAV8 capsid in cell supernatant or cell lysate. The assay uses two labeled antibodies: one coupled to a donor fluorophore, the other to an acceptor. In presence of AAV8 capsid in a cell extract or supernatant the addition of these conjugates brings the donor fluorophore into close proximity with the acceptor, and thereby generates a FRET signal. Its intensity is directly proportional to the concentration of the capsid present in the sample and provides a means of assessing any changes caused by experimental variability under a no-wash assay format.

assay principle AAV8
AAV8 capsid assay protocol

The AAV8 capsid assay protocol, using a 384-well small volume white plate,  is described on the right. 5 µL of sample or standard and 5 µL of diluent are dispensed directly into the detection plate for detection by HTRF® reagents. The antibodies labeled with HTRF fluorophores were added before an overnight incubation. The assay can be run in up to a 1536-well format by simply resizing each addition volume proportionally.

assay protocol AAV8

 

Assay details

AAV8 capsid assay specifications
assay specification AAV8
Sample size 5 µL
Final assay volume 20 µL
Time to results Overnight at RT
Detection limit (LOD) in diluent 2.50E+08 VP/mL
Dynamic Range 3.09E+09 – 2.50E+11 VP/mL
Sample compatibility

From raw harvest material to the final product

Supernatant, Cell Lysate (LB#3)

 

Analytical performance

Precision
Intra-assay
Sample Mean [AAV8] (VP/mL) CV
1 1.60E+11 3%
2 1.00E+10 4%
3 5.00E+10 5%
  Mean CV 4%

Each of the 3 samples was measured 24 times, and % CV was calculated for each sample.

Inter-assay
Sample Mean [AAV8] (VP/mL) CV
1 2.00E+11 1%
2 1.00E+11 7%
3 5.00E+10 8%
  Mean CV 5%

Each of the samples was measured in 3 independent experiments performed by different operators, and % CV was calculated for each sample.

Dilutional linearity

 

The excellent % of recovery obtained from these experiments shows the good dilution linearity of the assay. Samples were AAV8 empty capsids serially diluted with the kit DIL5 diluent.

Dilution Factor

[AAV8] Expected

(VP/mL)

[AAV8] Measured

(VP/mL)

Dilution Recovery

Neat

-

2.00E+11

100%

2

1.05E+11

1.03E+11

98%

4

5.26E+10

4.82E+10

92%

8

2.63E+10

2.31E+10

88%

16

1.31E+10

1.21E+10


92%

Mean

   

94%

 

 

Interferences

Different cell lines (SF9 and HEK293), representative of AAV manufacturing processes,  were seeded in T175 flasks in complete culture medium at 37°C, 5% CO2. The cells were then lysed with 3 mL of lysis buffer #3 (1X) for 30 minutes at RT under gentle shaking.

AAV8 capsid at 6.0E+10 VP/mL was spiked in several dilutions of SF9 or HEK293 cell lysates  not expressing AAV capsids (corresponding to different amount of total protein concentration, mg/mL). All samples, including lysates without capsid added were measured in the assay.

As expected, no AAV8 was detected in SF9 or HEK293 control cell lysates. However, for an accurate quantification of AAV8 concentration it is important to ensure that total protein concentration is below 1 mg/mL for SF9 cell lysates and HEK293 cell lysates by using dilution with lysis buffer #3.

At higher cell lysate total protein concentration, there is an interference that could affect the accuracy of the AAV8 concentration measurement.

[AAV8]

(VP/mL)

[Total Protein]

SF9 cell lysates

Spiked Sample (mg/mL)

Recovery

6.0E+10 1 101%
0.5 107%
0.25 105%
0.125 160%
0.05 102%

[AAV8]

(VP/mL)

[Total Protein]

HEK293 cell lysates

Spiked Sample (mg/mL)

Recovery

6.0E+10 1 109%
0.5 107%
0.25 102%
0.125 107%
0.05 111%
Antigen spike and recovery

Three different concentrations of AAV8 capsid were independently mixed with SF9 or HEK293 cell lysates diluted in lysis buffer #3 at 1 mg/ml. The measured concentrations were compared to the expected values and expressed as percentage of recovery.

Sample

[AAV8] Standard

(VP/mL)


SF9 cell lysate (1 mg/ml)

Recovery

1

1,34E+10

116%

2

2,93E+10

108%

3

5,41E+10

115%

 


Mean CV

113%

Sample

[AAV8] Standard

(VP/mL)


HEK293 cell lysate (1 mg/ml)

Recovery

1

1,34E+10

118%

2

2,93E+10

104%

3

5,41E+10

116%

 


Mean CV

113%


Cross reactivities 

Cross reactivities were assessed using other serotypes from the AAV family. Standard curves were generated for each serotype using AAV capsids diluted in the kit diluent.

5 µL of capsids were transferred into a white detection plate (384 low volume), followed by 5 µL of diluent then 10 µL of the HTRF AAV8 capsid detection reagents. The HTRF signal was recorded after an overnight incubation at room temperature.

Signals were interpolated on the assay standard curve to interpolate concentrations. The assay is specific to AAV8 as other serotypes were not detected using this assay.

Empty AAVs Particles

Cross Reactivity

AAV8

100%

AAV1

No

AAV2

No

AAV3B

No

AAV5

No

AAV6

No

AAV9

No

 

Assay validation

Validation of HTRF AAV8 capsid detection on full and empty AAV8 particles

To demonstrate the detection of both full and empty AAV8 capsids, recognition of full AAV8-CMV-eGFP and empty AAV8 capsids was analyzed in the assay. A large range of AAV8-CMV-eGFP concentration (GC/mL) was calculated in VP/mL using an independent sample quantitation assay.

5 µL of full or empty capsids diluted in the kit diluent were then transferred into a white detection plate (384 low volume), followed by 5 µL of diluent and 10 µL of the HTRF AAV8 capsid detection reagents. The HTRF signal was recorded after an overnight incubation at room temperature.

As expected, the HTRF AAV8 capsid detection assay can detect in the same way both full and empty AAV8 capsids.

assay validation AAV8

 

Resources

Are you looking for resources, click on the resource type to explore further.

1-6 of 6 Resources
Whitepaper Icon
Whitepaper
Adeno-Associated Virus (AAV) Vectors Manufacturing

What Are the Challenges and Solutions?

All across the globe, AAVs are getting the attention of scientists and companies working in...

Whitepaper Icon
Whitepaper
Complete gene therapy review in a single industry report

With the increased understanding of molecular and cellular medicine, more specific and efficient gene transfer vectors are now...

Brochure Icon
Brochure
HTRF assays and reagents catalog

Discover the versatility and precision of Homogeneous Time-Resolved Fluorescence (HTRF) technology. Our HTRF portfolio offers a...

Guide Icon
Guide
HTRF solutions, guide to major applications

This guide provides you an overview of HTRF applications in several therapeutic areas.

Whitepaper Icon
Whitepaper
Shifting the treatment paradigm: the promise of gene therapy for neurodegenerative diseases

Neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, and Huntington’s, are complex disorders that affect millions...

Publication Icon
Literature - Publication Review
Using gene therapy to correct certain genetic disorders

See how researchers boost their gene therapy studies with Revvity technologies

The absence or mutation of protein is a factor that...

Scroll Icon